Microvascular Therapeutic Announces Investment from the Nucleus Institute

December 4, 2025 — Salt Lake City, UT — The Nucleus Institute’s investment committee has unanimously approved and completed an investment in Microvascular Therapeutics Inc. (MVT) through MVT’s convertible note.

“This is our first institutional investor,” said Dr. Evan Unger, MD, CEO and Founder of MVT. “Their support is a strong validation of our investor readiness following Nucleus’ extensive due diligence.”

“We are currently planning a priced round to fund a Phase III clinical study for our contrast agent, CardiSon (MVT-100),” said Chief Business Officer, Dr. Thom Tulip, PhD. “We are optimistic that Nucleus’ investment will help accelerate our momentum.”

“We are thrilled to welcome MVT into the Nucleus portfolio,” said Kristin Wihera, Director of Funder Operations at Nucleus. “We were drawn to MVT by Dr. Unger’s track record and the transformative potential of their technology.”

About Microvascular Therapeutics

Microvascular Therapeutics (MVT) is developing next-generation ultrasound contrast and theranostic agents with the potential to transform cardiovascular and oncology imaging and therapy. Its lead product, MVT-100, is designed to improve the safety, performance, and accessibility of ultrasound contrast worldwide.

About Nucleus Institute

The Nucleus Institute is Utah’s state-backed investment organization dedicated to supporting high-potential life science, health care, and technology companies through early-stage capital and applied commercialization resources.

Media Contact

Bryan Unger

Microvascular Therapeutics

Email: b.unger@mvtpharma.com

Phone: (520) 624-6699

Disclaimer:

This press release contains forward-looking statements regarding Microvascular Therapeutics’ lead ultrasound contrast agent, CardiSon (MVT-100), including its potential clinical benefits, safety profile, regulatory pathway, and commercialization prospects. These statements are based on current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from those anticipated. Such risks include, but are not limited to, the outcomes of ongoing and future clinical trials, regulatory review and approval processes, manufacturing scale-up, market acceptance, and the availability of financing. Microvascular Therapeutics undertakes no obligation to update or revise any forward-looking statements contained herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.